KIT and gastrointestinal stromal tumor: KTN-0158, LOP-628, MK-1496, OPB-51602, perifosine, refametinib and XL-820 were ceased at phase I. AB-515, AZD-3229, c-kit inhibitors (Deciphera), gastrointestinal stromal tumor therapy (Array BioPharma), HYGT-110, LWEL-1808 and MAAC-003 were ceased at the preclinical phase.